Bora Biologics Co., Ltd.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
CDMO Contract Process Development and Manufacturing Services
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2021
Unified Business No.
90552221
Status
Closed
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Acquired(2025)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Bora Biologics Co., Ltd. is a subsidiary of Bora Pharmaceuticals, Taiwan's largest pharmaceutical group, focusing on the contract manufacturing of macromolecular drugs. Formerly known as Baofeng Biotech, it was renamed Bora Biologics Co., Ltd. in 2023. In 2025, it merged with Tanvex and was dissolved. Bora Biologics Co., Ltd. established its presence in the Hsinchu Biomedical Park, setting up a global antibody drug R&D center and a pilot plant that complies with cGMP standards. It is one of the few domestic companies with macromolecular biologic drug R&D capabilities and production facilities certified by multiple countries. The core of its biotech R&D and manufacturing team has completed dozens of batches of clinical trial drug production, and the produced protein biologics have been used in Phase I to Phase III human clinical trials in more than a dozen countries, including Taiwan, Europe, the United States, Australia, and China.
(The content above was translated by AI.)
(The content above was translated by AI.)
